Provided by Tiger Trade Technology Pte. Ltd.

Urogen Pharma Ltd.

21.67
-0.2300-1.05%
Post-market: 21.670.00000.00%19:47 EST
Volume:305.27K
Turnover:6.63M
Market Cap:1.01B
PE:-6.26
High:22.25
Open:21.90
Low:21.45
Close:21.90
52wk High:30.00
52wk Low:3.42
Shares:46.81M
Float Shares:37.03M
Volume Ratio:0.40
T/O Rate:0.82%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4606
EPS(LYR):-2.9590
ROE:-1481.26%
ROA:-33.96%
PB:-8.79
PE(LYR):-7.32

Loading ...

Urogen Pharma Chief Medical Officer Mark Schoenberg Sells Common Shares

Reuters
·
Feb 05

Guggenheim Sticks to Its Buy Rating for Urogen Pharma (URGN)

TIPRANKS
·
Feb 02

UroGen Pharma Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jan 23

UroGen Pharma Grants Inducement RSUs to 14 New Employees

Reuters
·
Dec 05, 2025

UroGen Pharma Chief Medical Officer Mark Schoenberg Sells Common Shares

Reuters
·
Nov 21, 2025

UGN-103 Phase 3 Success and FDA Support Could Be a Game Changer for UroGen Pharma (URGN)

Simply Wall St.
·
Nov 16, 2025

Ladenburg Thalmann & Co. Sticks to Its Buy Rating for Urogen Pharma (URGN)

TIPRANKS
·
Nov 08, 2025

Stock Track | UroGen Pharma Plummets 5.06% in Pre-market: Potential Profit-Taking After Recent Surge

Stock Track
·
Nov 07, 2025

Stock Track | Urogen Pharma Plummets 5.06% in Pre-market Despite Recent Positive Developments

Stock Track
·
Nov 07, 2025

Stock Track | UroGen Pharma Plunges 8.16% as Q3 Revenue Misses Estimates Despite Promising Pipeline

Stock Track
·
Nov 07, 2025

Stock Track | Urogen Pharma Plunges 8% Following Q3 Earnings Miss and Mixed Outlook

Stock Track
·
Nov 07, 2025

UroGen Q3 2025 Earnings Call Summary and Q&A Highlights: Zasturi Launch and Pipeline Progress

Earnings Call
·
Nov 07, 2025

UroGen (URGN) Q3 2025 Earnings Call Transcript

Motley Fool Transcribing
·
Nov 07, 2025

UroGen Says FDA Agrees to New Drug Application for UGN-103 Based on Phase 3 Data

MT Newswires Live
·
Nov 06, 2025

Stock Track | Urogen Pharma Plunges 9.37% Pre-market on Q3 Revenue Miss and Declining Cash Position

Stock Track
·
Nov 06, 2025

Stock Track | Urogen Pharma Plunges 9.37% Pre-market Following Q3 Revenue Miss

Stock Track
·
Nov 06, 2025

Earnings Flash (URGN) UroGen Pharma Posts Q3 Net Loss $0.69 a Share, vs. FactSet Est of $0.69 Loss

MT Newswires Live
·
Nov 06, 2025

UroGen Pharma reports Q3 revenue of $27.5 million

Reuters
·
Nov 06, 2025

UroGen Pharma Reports 77.8% Complete Response Rate in Phase 3 UTOPIA Trial for UGN-103

Reuters
·
Nov 06, 2025

Urogen Pharma Ltd expected to post a loss of 69 cents a share - Earnings Preview

Reuters
·
Nov 04, 2025